Viva In Vitro Diagnostics has developed VIVA‑ELISA®, an ELISA‑type immunoassay that detects ASC‑Speck, a biomarker of NLRP3 inflammasome activation, to identify early immune deterioration in critically ill patients. The test delivers quantitative results within hours, integrates with standard laboratory workflows, and enables hospitals and health‑system labs to stratify sepsis risk, personalize treatment, and reduce mortality and intensive‑care costs.
Funding
$1.4M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Current sepsis diagnostics detect the condition only after symptoms appear, do not assess the patient’s immune status, and often take hours to deliver results, leading to delayed treatment and high mortality.
Solution
Viva In Vitro Diagnostics offers VIVA‑ELISA®, a laboratory‑based immunoassay that measures activation of the NLRP3 inflammasome via ASC‑Speck detection. The test provides an early, quantitative indication of immune deterioration in critically ill patients, enabling clinicians to stratify sepsis risk before clinical deterioration. Results are delivered quickly and integrate with existing clinical protocols, supporting personalized therapeutic decisions. By identifying high‑risk patients early, the platform aims to reduce sepsis‑related mortality, intensive‑care stays, and overall healthcare costs. The technology is protected by an international PCT patent and is being advanced toward regulatory approval (EU IVDR, US FDA Class II 510(k)).
Target Audience
Primary customers are hospitals, intensive‑care units, and health‑system laboratories seeking early sepsis screening tools, as well as pharmaceutical companies developing targeted therapies for sepsis and related inflammatory conditions.
Features
- ELISA‑type assay that detects ASC‑Speck, a specific biomarker of NLRP3 inflammasome activation
- Compatible with standard laboratory equipment and existing clinical workflows
- Rapid turnaround time delivering results within hours, suitable for emergency and ICU settings
- Quantitative readout enabling precise risk stratification and personalized treatment planning
- Proprietary patent (WO 2020/182964 A1) covering the biomarker detection method
- Built on ISO 13485‑compliant quality management and incorporates blockchain‑based data integrity tracking